BioNTech Sets Its Own September Test After Riding a Rival's Tailwind
Published on 08/23/2026 at 04:51 | Redaktion boerse-global.de
The calendar at the IASLC World Conference on Lung Cancer in Seoul, running September 12-15, now carries two distinct markers for BioNTech. The Mainz-based biotech confirmed Thursday it will unveil first-ever global clinical data on a combination of its PD-L1xVEGF bispecific Pumitamig with the B7H3-directed antibody-drug conjugate Elfetabart Drozuntecan in lung cancer. Alongside that, the company will present updated overall survival figures from the Phase 3 PRESERVE-003 trial evaluating Gotistobart (BNT316) in advanced squamous non-small cell lung cancer.
The announcement lands at a moment when the stock is already running hot — though much of that heat has been borrowed. US-listed shares climbed sharply Wednesday after Moderna and Merck reported positive Phase 3 results for a personalized melanoma vaccine. Reuters noted the readout rippled across the entire mRNA and cancer vaccine sector, lifting BioNTech even though its own oncology vaccine work, developed with Roche, remains in mid-stage testing with results years away.
Two Data Sets, One Measuring Stick
Presenting two oncology readouts at the same conference underscores how aggressively BioNTech is pushing its pipeline beyond the Covid franchise that made it a household name. The Pumitamig-Elfetabart Drozuntecan pairing represents a novel combination strategy, while the PRESERVE-003 survival data tackle one of oncology's toughest endpoints. Investors will likely treat both as a barometer of whether the company's diversification story has genuine legs.
Speaking of managing risk — the same discipline that guides clinical development applies to workplace safety. A free toolkit with 41 ready-to-use templates and checklists helps you document hazards and keep your compliance obligations under control. Download the free Risk Assessment Toolkit
The Seoul presentation follows a string of disclosures designed to cement that narrative. Roughly three weeks ago, alongside quarterly earnings, BioNTech reported a confirmed objective response rate of 62.5 percent in a global Phase 2 study of Pumitamig combined with chemotherapy in non-small cell lung cancer. The upcoming global first data on the Elfetabart Drozuntecan combination now serve as the next checkpoint on whether that signal holds in broader patient populations.
Regulatory Tailwind and a Running Buyback
Adding weight to the story is a regulatory green light: the European Commission granted marketing authorization for the XFG-variant-adapted Covid-19 vaccine from Pfizer and BioNTech for the 2026/2027 season. The core vaccine business keeps humming along, even if it no longer anchors the company's future narrative.
Financially, BioNTech sits on solid footing after trimming its full-year 2026 revenue outlook to a range of EUR 1.6-1.9 billion. As of June 30, the company held EUR 16.6 billion in liquid assets and securities. From its USD 1 billion share repurchase program, it had already deployed USD 152 million — a signal that management sees value in its own equity despite the recent rally. The supervisory board has confirmed the buyback will continue, a program that permits repurchasing up to 4.2 percent of outstanding shares.
Just as BioNTech is de-risking its future, you can de-risk your workplace. Over 37,000 UK businesses already use this free Health & Safety Toolkit to stay compliant with COSHH, PUWER and the Health & Safety at Work Act 1974. Get the free Health & Safety Toolkit
A Rally With a Narrow Margin for Error
The market has been generous lately. The stock closed Friday at EUR 99.80, up 5.1 percent in a single session. Over the past week, it has gained 24 percent, and it is up 23 percent since the start of the year. That leaves it just 5.7 percent shy of its 52-week high of EUR 105.80, reached in January — a gap that could narrow quickly given the current momentum.
Not everyone is convinced. Wall Street Zen downgraded the stock from "Hold" to "Sell" in early August, a call that looks increasingly like a snapshot from a different market regime given the subsequent price action and pipeline headlines.
With Seoul now firmly on the horizon, the oncology pipeline becomes the decisive variable for near-term price direction. The market has already priced in considerable optimism; the question is whether the global first data on the Pumitamig combination and the updated Gotistobart survival figures can meet that elevated bar. Solid results would reinforce the thesis that BioNTech is genuinely executing its transition from pandemic vaccine maker to oncology-driven biopharma. Disappointing numbers, by contrast, would hit a stock that has been trading heavily on anticipation.
